

BLAU FARMACÊUTICA S.A.

Publicly Held Company
NIRE 35.300.416.406
CVM Code No. 2462-7

MATERIAL FACT**Update on €50 Million Convertible Loan to Prothya**

BLAU FARMACÊUTICA S.A. (Ticker: **BLAU3**; "**Blau**" or "**Company**"), in compliance with the provisions of CVM Resolution No. 44, of August 23, 2021, as amended, informs its shareholders and the market in general that it has decided not to convert the amount of its loan into equity ("Convertible Loan") of Prothya Biosolutions, a human plasma fractionator with facilities in the Netherlands and Belgium, responsible for the production of medicines such as Immunoglobulin, Human Albumin, Prothrombin Complex, among other plasma-derived products. The Convertible Loan was executed with Prothya Biosolutions Belgium B.V. ("Prothya BE") and Stichting Administratiekantoor Prothya Holding ("STAK" and, together with Prothya BE, "Prothya") on August 30, 2023, as disclosed in a material fact published by the Company on that date.

The decision was made following a thorough evaluation by our Board of Directors, considering that, since the date the Convertible Loan was granted, Prothya has not delivered the operational results expected by Blau, which were a contractual and strategic condition for a potential conversion of the loan amount into Prothya shares.

Additionally, Blau was informed by Prothya that its shareholders have signed a preliminary agreement for the sale of 100% of the company's share capital to a third-party buyer, with closing subject to the completion of a series of preliminary steps and conditions precedent, including obtaining regulatory approvals and conducting formal consultations with the respective Works Councils, as required under applicable local laws.

According to the terms of the aforementioned preliminary agreement, if the sale transaction is completed, the buyer will fully assume Prothya's liabilities and, as an additional condition precedent to closing, will be required to pay Blau the full amount of the Convertible Loan, in the historical amount of €50 million, plus accrued interest up to the settlement date.

It is important to emphasize that Prothya's results are not consolidated into Blau's financial statements, as the investment was of a strategic nature.

The Company will keep its shareholders and the market informed about the closing of the Sale Transaction and the effective repayment of the Convertible Loan.

Cotia, July 9, 2025

Douglas Leandro Rodrigues
Chief Financial and Investor Relations Officer

About Blau Farmacêutica:

Blau is a leading pharmaceutical company in the institutional segment and a pioneer in biotechnology, with a portfolio of private brands of highly complex drugs focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectious diseases, operating in several therapeutic classes. Blau has a continental presence, currently in 7 Latin American countries – Brazil, Argentina, Colombia, Chile, Ecuador, Peru, Uruguay and the United States, and has a modern pharmaceutical industrial complex, consisting of five industrial plants, with state-of-the-art technology, dedicated to the production of biological, oncological, antibiotic, injectable anesthetics and biotechnological drugs.